A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

This study is testing a combination of two cancer drugs — fruquintinib (a targeted therapy) and tislelizumab (an immunotherapy) — in people with colorectal cancer who have no visible signs of disease on scans but still show traces of cancer DNA in their blood (called ctDNA), suggesting a high risk of the cancer coming back. **You may be eligible if...** - You have confirmed colorectal cancer (microsatellite stable type, MSS) - You have completed curative treatment for stage II, III, or IV colorectal cancer, including at least 3 months of oxaliplatin-based chemotherapy - There is no visible cancer on recent imaging - A blood test (ctDNA assay, such as Signatera) performed at MD Anderson or a certified lab shows cancer DNA in your blood **You may NOT be eligible if...** - Your ctDNA test is negative (no cancer DNA detectable) - You have visible cancer on scans - Your colorectal cancer has a microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) profile (a different category that responds to other treatments) Talk to your doctor to see if this trial is right for you.